Registration number: 04702062

Research Donors Limited

Contents

Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3 to 9

Research Donors Limited

Company Information

Director

Mr Michael Kerins

Registered office

Unit C14 Poplar Business Park Prestons Road London E14 9RL

Auditors

TT&W Limited 5 High Green Great Shelford Cambridge CB22 5EG

Research Donors Limited

(Registration number: 04702062)
Balance Sheet as at 31 December 2024

	Note	2024 £	2023 £
Fixed assets
Tangible assets	4	88,180	225,234
Current assets
Stocks	5	427,539	394,266
Debtors	6	1,231,112	457,040
Cash at bank and in hand		366,851	1,202,141
		2,025,502	2,053,447
Creditors: Amounts falling due within one year	7	(254,948)	(611,146)
Net current assets		1,770,554	1,442,301
Total assets less current liabilities		1,858,734	1,667,535
Provisions for liabilities		(18,443)	(52,761)
Net assets		1,840,291	1,614,774
Capital and reserves
Called up share capital	8	1,053	1,053
Retained earnings		1,839,238	1,613,721
Shareholders' funds		1,840,291	1,614,774

 

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 2 July 2025
 

......................................... Mr Michael Kerins Director

Research Donors Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

1	General information

The company is a private company limited by share capital, incorporated in England and Wales.

The company's registered number is 04702062.

The address of its registered office is:
Unit C14 Poplar Business Park
Prestons Road
London
E14 9RL

These financial statements were authorised for issue by the director on 2 July 2025.

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Summary of disclosure exemptions

The company is exempt from the requirement to prepare group accounts under FRS 102 Section 1A being itself a wholly owned subsidiary undertaking. Details of the group parent can be found under note 11 below.

Research Donors Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Audit report

The Independent Auditor's Report was unqualified.

The name of the Senior Statutory Auditor who signed the audit report on 2 July 2025 was Imran Tayabali BSc FCA, who signed for and on behalf of TT&W Limited.

.........................................

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Research Donors Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Improvements to property	33% straight line
Plant and machinery	33% straight line
Fixtures and fittings	25% reducing balance & 33% straight line

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Research Donors Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3	Staff numbers

The average number of persons employed by the company (including the director) during the year, was 18 (2023 - 15).

Research Donors Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

4	Tangible assets

	Improvements to property  £	Fixtures and fittings £	Plant and machinery £	Total £
Cost or valuation
At 1 January 2024	301,630	61,097	408,539	771,266
Additions	-	1,575	2,651	4,226
At 31 December 2024	301,630	62,672	411,190	775,492
Depreciation
At 1 January 2024	265,483	32,350	248,199	546,032
Charge for the year	20,315	13,847	107,118	141,280
At 31 December 2024	285,798	46,197	355,317	687,312
Carrying amount
At 31 December 2024	15,832	16,475	55,873	88,180
At 31 December 2023	36,147	28,747	160,340	225,234

5

Stocks

	2024 £	2023 £
Finished goods and goods for resale	427,539	394,266

6

Debtors

Current	Note	2024 £	2023 £
Trade debtors		241,147	374,956
Amounts owed by related parties	10	750,000	-
Prepayments		238,883	80,581
Other debtors		1,082	1,503
		1,231,112	457,040

Research Donors Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

7

Creditors

Creditors: amounts falling due within one year

	2024 £	2023 £
Due within one year
Trade creditors	65,688	92,144
Amounts owed to group undertakings and undertakings in which the company has a participating interest	43,466	22,617
Taxation and social security	105,048	438,268
Accruals and deferred income	40,746	58,117
	254,948	611,146

8	Share capital

Allotted, called up and fully paid shares

	2024		2023
	No.	£	No.	£
Ordinary of £1 each	1,053	1,053	1,053	1,053

9	Obligations under leases and hire purchase contracts

Operating leases

The total of future minimum lease payments is as follows:

	2024 £	2023 £
Not later than one year	211,436	153,064
Later than one year and not later than five years	848,821	218,567
Later than five years	1,096,394	-
	2,156,651	371,631

The amount of non-cancellable operating lease payments recognised as an expense during the year was £154,402 (2023 - £122,659).

Research Donors Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

10	Related party transactions

Director's loans are made on an interest free and unsecured basis.

Transactions with the director

2024	At 1 January 2024 £	Advances to director £	Repayments by director £	At 31 December 2024 £
Mr Michael Kerins
VAT amounts due and related advice	1,450	1,029	(1,450)	1,029

 

2023	At 1 January 2023 £	Advances to director £	Repayments by director £	At 31 December 2023 £
Mr Michael Kerins
VAT amounts due and related advice	92,433	1,450	(92,433)	1,450

Loans to related parties

2024	Parent £	Total £
Advanced	750,000	750,000
At end of period	750,000	750,000

Terms of loans to related parties

A loan of £750,000 has been advanced during the year ending 31st December 2024 to parent company Europa Biosite Holding AB registered in Sweden (company no. 559210-7428). Parent company loans are made on an interest free and unsecured basis.
 

11	Relationship between entity and parents

The parent of the largest group in which these financial statements are consolidated is Europa Biosite Holding AB, incorporated in Sweden.

The address of Europa Biosite Holding AB is:
Propellervagen 4a
SE-183 62 Taby
Sweden